274 related articles for article (PubMed ID: 30587523)
21. The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
Shakfa N; Li D; Nersesian S; Wilson-Sanchez J; Koti M
Br J Cancer; 2022 Sep; 127(4):603-611. PubMed ID: 35383278
[TBL] [Abstract][Full Text] [Related]
22. An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer.
Huang S; Hu H; Tang G; Liu K; Luo Z; Zeng W
Arch Virol; 2023 Mar; 168(4):128. PubMed ID: 37002434
[TBL] [Abstract][Full Text] [Related]
23. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
[TBL] [Abstract][Full Text] [Related]
24. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.
Khoo LT; Chen LY
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30446584
[TBL] [Abstract][Full Text] [Related]
25. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
26. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
27. A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1.
Li K; Liang J; Lin Y; Zhang H; Xiao X; Tan Y; Cai J; Zhu W; Xing F; Hu J; Yan G
Oncotarget; 2016 Jul; 7(30):48443-48455. PubMed ID: 27374176
[TBL] [Abstract][Full Text] [Related]
28. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly.
Dansako H; Ueda Y; Okumura N; Satoh S; Sugiyama M; Mizokami M; Ikeda M; Kato N
FEBS J; 2016 Jan; 283(1):144-56. PubMed ID: 26471009
[TBL] [Abstract][Full Text] [Related]
29. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
31. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production.
Konno H; Yamauchi S; Berglund A; Putney RM; Mulé JJ; Barber GN
Oncogene; 2018 Apr; 37(15):2037-2051. PubMed ID: 29367762
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
34. Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer.
Zhang J; Chen Y; Chen X; Zhang W; Zhao L; Weng L; Tian H; Wu Z; Tan X; Ge X; Wang P; Fang L
Cell Death Differ; 2021 Jan; 28(1):139-155. PubMed ID: 32678307
[TBL] [Abstract][Full Text] [Related]
35. Evasion of the STING DNA-Sensing Pathway by VP11/12 of Herpes Simplex Virus 1.
Deschamps T; Kalamvoki M
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592536
[TBL] [Abstract][Full Text] [Related]
36. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Shi F; Su J; Wang J; Liu Z; Wang T
Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
[TBL] [Abstract][Full Text] [Related]
37. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
38. cGAS-STING pathway in oncogenesis and cancer therapeutics.
Hoong BYD; Gan YH; Liu H; Chen ES
Oncotarget; 2020 Jul; 11(30):2930-2955. PubMed ID: 32774773
[TBL] [Abstract][Full Text] [Related]
39. Zika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells
Kaid C; Goulart E; Caires-Júnior LC; Araujo BHS; Soares-Schanoski A; Bueno HMS; Telles-Silva KA; Astray RM; Assoni AF; Júnior AFR; Ventini DC; Puglia ALP; Gomes RP; Zatz M; Okamoto OK
Cancer Res; 2018 Jun; 78(12):3363-3374. PubMed ID: 29700002
[TBL] [Abstract][Full Text] [Related]
40. cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
